Cargando…
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
INTRODUCTION: Deciding on an optimal medication choice for type 2 diabetes is often challenging, due to the increasing number of treatment options. Canagliflozin is a novel glucose-lowering agent belonging to sodium–glucose co-transporter 2 (SGLT2) inhibitors. AIM: The aim of this study was to exami...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358960/ https://www.ncbi.nlm.nih.gov/pubmed/28352212 http://dx.doi.org/10.2147/CE.S109654 |